Physician's Weekly2h
Optimized Prescribing of SGLT2 Inhibitors and GLP-1 RAs in High-Risk Patients
The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...
Medscape19h
Oral GLP-1 Receptor Agonist Reduces CV Risk
Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...
The American Journal of Managed Care16h
SOUL Findings Highlight Cardiovascular Benefits Beyond Glycemic Control With Oral GLP-1
Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 ...